ALNYLAM PHARMACEUTICALS, INC. Interest Expense
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Interest Expense of $35.25 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-02
- ALNYLAM PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-03-31 was $35.25M, a 21.75% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-12-31 was $31.34M, a 4.76% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $30.89M, a 24.81% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-06-30 was $30.04M, a 29.51% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. interest expense for fiscal 2023 was $121.22M, a 22.28% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $155.97M, a 9.05% increase from fiscal 2021.
- ALNYLAM PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $143.02M, a 69.26% increase from fiscal 2020.
- ALNYLAM PHARMACEUTICALS, INC. interest expense for fiscal 2020 was $84.50M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $35.25M 10-Q · filed 2024-05-02 | $66.59M derived: sum of 2 quarters · filed 2024-05-02 | $97.48M derived: sum of 3 quarters · filed 2024-05-02 | $127.52M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | $31.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $62.23M derived: sum of 2 quarters · filed 2024-02-15 | $92.27M derived: sum of 3 quarters · filed 2024-02-15 | $121.22M 10-K · filed 2024-02-15 |
| 2023-09-30 | $30.89M 10-Q · filed 2023-11-02 | $60.93M derived: sum of 2 quarters · filed 2023-11-02 | $89.88M 10-Q · filed 2023-11-02 | $119.80M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-06-30 | $30.04M 10-Q · filed 2023-08-03 | $58.99M 10-Q · filed 2023-08-03 | $88.90M derived: sum of 3 quarters · filed 2024-05-02 | $129.99M derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-03-31 | $28.95M 10-Q · filed 2024-05-02 | $58.87M derived: sum of 2 quarters · filed 2024-05-02 | $99.95M derived: sum of 3 quarters · filed 2024-05-02 | $142.56M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $29.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $71.00M derived: sum of 2 quarters · filed 2024-02-15 | $113.61M derived: sum of 3 quarters · filed 2024-02-15 | $155.97M 10-K · filed 2024-02-15 |
| 2022-09-30 | $41.08M 10-Q · filed 2023-11-02 | $83.69M derived: sum of 2 quarters · filed 2023-11-02 | $126.06M 10-Q · filed 2023-11-02 | $162.87M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $42.61M 10-Q · filed 2023-08-03 | $84.97M 10-Q · filed 2023-08-03 | $121.79M derived: sum of 3 quarters · filed 2024-02-15 | $162.06M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $42.36M 10-Q · filed 2023-05-04 | $79.18M derived: sum of 2 quarters · filed 2024-02-15 | $119.45M derived: sum of 3 quarters · filed 2024-02-15 | $152.87M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $36.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $77.09M derived: sum of 2 quarters · filed 2024-02-15 | $110.51M derived: sum of 3 quarters · filed 2024-02-15 | $143.02M 10-K · filed 2024-02-15 |
| 2021-09-30 | $40.27M 10-Q · filed 2022-10-27 | $73.69M derived: sum of 2 quarters · filed 2022-10-27 | $106.20M 10-Q · filed 2022-10-27 | $134.72M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $33.42M 10-Q · filed 2022-07-28 | $65.93M 10-Q · filed 2022-07-28 | $94.45M derived: sum of 3 quarters · filed 2023-02-23 | $123.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $32.52M 10-Q · filed 2022-04-28 | $61.03M derived: sum of 2 quarters · filed 2023-02-23 | $89.76M derived: sum of 3 quarters · filed 2023-02-23 | $117.01M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $28.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $57.25M derived: sum of 2 quarters · filed 2023-02-23 | $84.50M derived: sum of 3 quarters · filed 2023-02-23 | $84.50M 10-K · filed 2023-02-23 |
| 2020-09-30 | $28.73M 10-Q · filed 2021-10-28 | $55.98M derived: sum of 2 quarters · filed 2021-10-28 | $55.98M 10-Q · filed 2021-10-28 | $55.98M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $27.25M 10-Q · filed 2021-08-03 | $27.25M 10-Q · filed 2021-08-03 | $27.25M derived: sum of 3 quarters · filed 2022-02-10 | $27.25M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $0.00 10-Q · filed 2021-04-29 | $0.00 derived: sum of 2 quarters · filed 2022-02-10 | $0.00 derived: sum of 3 quarters · filed 2022-02-10 | $0.00 derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $0.00 derived: sum of 2 quarters · filed 2022-02-10 | $0.00 derived: sum of 3 quarters · filed 2022-02-10 | $0.00 10-K · filed 2022-02-10 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | ||
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 | |||
| 2008-12-31 | $872.00K 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |